Editas Medicine Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Gilmore O’Neill
Geschäftsführender
US$2.4m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 26.8% |
| Amtszeit als Geschäftsführer | 2yrs |
| Eigentum des Geschäftsführers | 0.1% |
| Durchschnittliche Amtszeit des Managements | 1.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.4yrs |
Jüngste Management Updates
Recent updates
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Editas: Data Was Eagerly Anticipated But Failed To Impress
Nov 03Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$2m | US$641k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$195m |
| Jun 30 2023 | n/a | n/a | -US$206m |
| Mar 31 2023 | n/a | n/a | -US$219m |
| Dec 31 2022 | US$9m | US$356k | -US$220m |
Vergütung im Vergleich zum Markt: GilmoreDie Gesamtvergütung ($USD2.39M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD2.45M).
Entschädigung vs. Einkommen: GilmoreDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Gilmore O’Neill (60 yo)
2yrs
Amtszeit
US$2,392,309
Vergütung
Dr. Gilmore O’Neill, M. B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 2yrs | US$2.39m | 0.13% $ 546.1k | |
| CFO & Executive VP | 1.1yrs | US$2.69m | 0.028% $ 118.0k | |
| Executive VP & Chief Scientific Officer | less than a year | US$1.73m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 1.9yrs | US$1.14m | 0.041% $ 173.6k | |
| Co-Founder & Scientific Advisory Board Member | 11.4yrs | keine Daten | keine Daten | |
| Co-Founder & Scientific Advisory Board Member | 11.4yrs | keine Daten | keine Daten | |
| Executive VP and Chief Technical & Quality Officer | less than a year | keine Daten | keine Daten | |
| Corporate Communications & Investor Relations | no data | keine Daten | keine Daten | |
| Executive VP & General Counsel | no data | keine Daten | keine Daten | |
| Executive VP & Chief People Officer | 1.3yrs | keine Daten | keine Daten | |
| Executive VP and Chief Commercial & Strategy Officer | less than a year | keine Daten | keine Daten |
1.3yrs
Durchschnittliche Betriebszugehörigkeit
60yo
Durchschnittliches Alter
Erfahrenes Management: EDITDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | no data | US$2.39m | 0.13% $ 546.1k | |
| Co-Founder & Scientific Advisory Board Member | no data | keine Daten | keine Daten | |
| Co-Founder & Scientific Advisory Board Member | no data | keine Daten | keine Daten | |
| Independent Chairman of the Board | 2.8yrs | US$238.24k | 0% $ 0 | |
| Independent Director | 7.9yrs | US$208.06k | 0% $ 0 | |
| Independent Director | 7.1yrs | US$210.56k | 0.0024% $ 10.2k | |
| Independent Director | 6.3yrs | US$231.07k | 0.082% $ 345.9k | |
| Independent Director | 1.2yrs | US$264.88k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$213.06k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$215.06k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$205.56k | 0% $ 0 |
4.4yrs
Durchschnittliche Betriebszugehörigkeit
64.5yo
Durchschnittliches Alter
Erfahrener Vorstand: EDITDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).